Sign up now and fund within 24h to get free NKE, GPRO or DBX stock.T&Cs apply.
Redeem Now
Teladoc Inc

Kickstart your portfolio with a U.S. stock on us

Sign up and fund a new Wall St account and get a full U.S. share.T&Cs apply

Claim now
Kickstart your portfolio with a U.S. stock on us

About TDOC

Teladoc Health, Inc. provides virtual healthcare services. Its segments include Teladoc Health Integrated Care (Integrated Care) and BetterHelp. Integrated Care segment includes a suite of global virtual medical services including general medical, expert medical services, specialty medical, chronic condition management, mental health, and enabling technologies and enterprise telehealth solutions for hospitals and health systems. Services in this segment are distributed on a B2B basis. BetterHelp segment includes direct-to-consumer mental health platform. The online counseling and therapy services are provided via its network of over 35,000 licensed clinicians leveraging its platform for Web, mobile app, phone, and text-based interactions. Its Teladoc Health family of brands, including Teladoc and BetterHelp, deliver access to advice and resolution for an array of healthcare needs. Its Telecare brand is a tech-enabled provider of specialist and allied health care via virtual delivery.

Find out what a historical investment in Teladoc Inc would be worth today using our TDOC stock calculator.

Market Capitalisation

$1.60B

Price-earnings ratio

-

Dividend yield

0.00%

Volume

3.16M

High today

$8.91

Low today

$8.65

Open price

$8.68

52-week high

$9.89

52-week low

$4.40

Ready to start your investing journey with Stake?

Open an account

What is Teladoc Health (TDOC) and what do they do?

When you're sick these days, there's a new way to tell a doc.

Teladoc Health, Inc. is a virtual healthcare platform that provides telemedicine services in the United States. Intent on transforming the healthcare experience, the company gives clients a way to avoid long wait times in surgeries and clinics and receive medical expertise wherever they may be.

In their own words: “We aim to achieve our vision of making virtual care the first step on any healthcare journey by delivering, enabling and empowering integrated whole person virtual care services and experiences that span every stage of the healthcare journey.”

Founded in 2002 and headquartered in Purchase, New York, Teladoc Health offers a wide scope of client services and solutions. They cover everything from non-urgent, episodic needs such as the flu, all the way through to chronic, complex medical conditions including cancer, kidney disease, diabetes, hypertension and congestive heart failure.

How does Teladoc Health generate revenue?

The large majority of Teladoc Health’s revenue comes from monthly or yearly client subscriptions. The company categorises this subscription revenue as “access fees.”

Revenue also comes from per-telehealth visits; flat sums paid for individual appointments. Teladoc Health categorises this revenue as “visit fees.”

For FY2021 alone, 85% of the company’s revenue came from access fees while 13% came from visit fees.

Teladoc Health also earns revenue from recurring health system and provider access fees, as well as the sale and lease of medical robots, medical carts and digital tablets.

Is Teladoc Health profitable?

While revenue has grown steadily since Teladoc Health went public in 2015, the company has never made a profit. 

In fact, operating income recently sank deeper into red territory at minus US$74m, minus US$418m and minus US$239m in FY2019, FY2020 and FY2021 respectively.

What type of stock is TDOC? 

TDOC is a healthcare technology stock.

Who are Teladoc Health’s competitors?

While Teladoc Health is the industry’s current leader, competition in the telemedicine space is growing quickly.

Some of Teladoc Health’s competitors include Doximity (DOCS), GoodRX (GDRX), American Well (AMWL), 1Life Healthcare Inc. (ONEM), Doctor on Demand, MDLIVE and Sharecare (SHCR).

What happened between Teladoc Health (TDOC) and Livongo (LVGO)?

On 30 October 2020, Teladoc Health acquired Livongo, another digital health management firm, for US$18.5b cash and stock.

Under the terms of the acquisition, Livongo shareholders received 0.5920 shares of TDOC as well as US$4.24 for each Livongo share held.

Additionally, Livongo shareholders were also paid a special dividend of US$7.09.

Is TDOC stock a buy?

Teladoc Health has been unprofitable since going public in 2015 and yet the number of available shares continues to grow, diluting the stock’s value. Just between FY2020 and FY2021 the number of available shares rose from 91m to 157m.

Since its February 2021 high of over US$290, the TDOC stock price has dropped almost 80% down to the mid US$50 range.

Some investors believe that TDOC stock’s best days are behind us as the company’s competition is growing quickly. Other investors remain optimistic, focusing on revenue growth and future earnings potential gained by the Livongo acquisition.

Buying TDOC shares in Australia can be done through an online investing platform, such as Stake. Follow the simple steps below to start investing in Teladoc Inc in minutes.
  1. Sign up with some I.D. and zero paperwork
  2. Add funds to your account
  3. Make your first investment in TDOC

The ticker symbol for Teladoc Inc is TDOC.

One share of TDOC is valued at $8.80 as of 14 November 2026.

As of 14 November 2026 Teladoc Inc has a market cap of $1.60B.

The Teladoc Inc 52-week high stock price is $9.89.

The Teladoc Inc 52-week low stock price is $4.40.

Yes, the Stake investing platform allows you to buy TDOC shares and over 13,000 more stocks and ETFs across the ASX and Wall St.

This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.

Stake app

Invest in TDOC on Stake

  • Buy TDOC from US$3 brokerage
  • Invest in 11,000+ U.S. stocks and ETFs
  • Own a slice of TDOC from only US$10 with fractional shares
Get started

Stock shown for demonstrative purposes only. US$3 brokerage up to US$30,000.

TDOC related stocks

Footer


Made in Australia

Sydney, Australia


Get the app

Scan QR code to download the app

Stakeshop Pty Ltd, trading as Stake, ACN 610 105 505, is an authorised representative (Authorised Representative No. 1241398) of Stakeshop AFSL Pty Ltd (Australian Financial Services Licence no. 548196). Stake SMSF Pty Ltd ACN 648 283 532 (‘Stake Super’) is not licensed to provide financial product advice under the Corporations Act. This specifically applies to any financial products which are established if you instruct Stake Super to set up a self managed super fund (‘SMSF’). When you sign up to Stake Super, you are contracting with Stake SMSF Pty Ltd who will assist in the establishment of a SMSF under a ‘no advice model’. You will also be referred to Stakeshop Pty Ltd to enable your trading account and bank account to be set up in order to use the Stake Website and/or App. For more information about SMSFs, see our SMSF Risks page. The Stake Accumulate Fund (ARSN 680 653 374) is issued by K2 Asset Management Ltd (ABN 95 085 445 094 AFSL 244 393), a wholly owned subsidiary of K2 Asset Management Holdings Ltd (ABN 59 124 636 782). The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake and Stake Super, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice given by Stake is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Financial Services Guide, Terms & Conditions, Privacy Policy and Disclaimers before deciding to invest on or use Stake or Stake Super. By using our website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake and Stake Super are registered trademarks in Australia.

This information is being provided in connection with the Australian retail offer component of the initial public offering of shares of Class A common stock (“Shares”) in Anthropic, PBC (“Anthropic”) (“IPO”). The Australian retail offer is an offer of newly issued Shares by Anthropic (“Australian Retail Offer”) made under the Australian prospectus lodged with the Australian Securities and Investments Commission on 11 November 2026 (“Australian Prospectus”). This information does not form part of the Australian Prospectus, and anyone considering applying for Shares under the Australian Retail Offer should rely only on information in the Australian Prospectus and any supplementary or replacement Australian Prospectus. A copy of the Australian Prospectus is available on ipo.anthropic.com. Further information about Anthropic, the IPO, the Shares and the risks of investing in Anthropic is set out in the Australian Prospectus. Anyone considering applying for Shares under the Australian Retail Offer should read and consider the Australian Prospectus in full in deciding whether to acquire Shares under the Australian Retail Offer. Anyone who wants to acquire Shares under the Australian Retail Offer will need to complete the application form that accompanies the Australian Prospectus, in accordance with the process set out in the Australian Prospectus and any other instructions from their broker. Anthropic has applied to list its Class A common stock on the Nasdaq Global Select Market under the symbol “ANT”. Anthropic will not be applying for listing on the Australian Securities Exchange.

Us securities law disclaimer

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (“SEC”) but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This communication does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to its acceptance after the effective date. The prospectus in the registration statement and other documents Anthropic has filed with the SEC include additional information about Anthropic and the offering. Investors may get these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. The registration statement (including the US prospectus) is available at www.sec.gov

Copyright © 2026 Stake. All rights reserved.